6590-93-8

Usage

Uses

Used in Chemical Experiments:
3,5-Dichlorophenyl isothiocyanate is used as a chemical intermediate for various chemical experiments and processes. Its unique molecular structure and reactivity make it a valuable component in the synthesis of other compounds.
Used in Pharmaceutical Research:
3,5-Dichlorophenyl isothiocyanate is used as a research compound in the development of new pharmaceuticals. Its properties and interactions with other molecules can provide insights into potential drug candidates and their mechanisms of action.
Used in Industrial Processes:
3,5-Dichlorophenyl isothiocyanate is used as a chemical intermediate in specific industrial processes. Its reactivity and unique structure contribute to the production of various industrial chemicals and materials.
Used in Analytical Chemistry:
3,5-Dichlorophenyl isothiocyanate is used as a derivatization agent in analytical chemistry. Its ability to react with certain functional groups can aid in the identification and quantification of compounds in complex mixtures.

InChI:InChI=1/C7H3Cl2NS/c8-5-1-6(9)3-7(2-5)10-4-11/h1-3H

Upstream product

• 463-71-8 thiophosgene 
• 626-43-7 3,5-Dichloroaniline 
• 618-62-2 3,5-dichloro-1-nitrobenzene 
• 5344-44-5 3-nitro-5-chloroaniline 

Downstream Products

• 134168-85-7 N-(3,5-dichlorophenyl)-N'-t-pentylthiourea 
• 134168-89-1 N-(3,5-dichlorophenyl)-N'-(1,2,2-trimethylpropyl)thiourea 
• 213209-22-4 5-(4-bromobenzyl)-3-(3,5-dichlorophenyl)-5-methyl-2-thioxoimidazolidin-4-one 
• 905917-06-8 2-cyano-2-(3,5-dichloro-phenylthiocarbamoyl)-acetamide 
• 907603-93-4 1,2-dimethyl-1H-indazolium-3-(N-3,5-dichlorophenyl)thioamidate 
• 33591-19-4 3-(3,5-dichloro-phenyl)-2-thioxo-imidazolidin-4-one 
• 444342-87-4 (3,5-dichlorophenyl)-N-[5-({[(3,5-dichlorophenyl)amino]thioxomethyl}amino)-3-{[3-(trifluoromethyl)phenyl]amino }phenyl]formamide 
• 444343-10-6 [(3,5-Dichlorophenyl)amino]{[2-bromo-5-(naphthylmethoxy)phenyl]amino}methane-1-thione 
• 268207-25-6 2-(4-chlorophenylsulfonyl)-3-(3,5-dichlorophenylamino)-3-methylsulfanyl-2-propenenitrile 
• 1356927-95-1 1-(3,5-dichlorophenyl)-3-(isoquinolin-5-yl)thiourea 

Relevant academic research and scientific papers

Design, synthesis, X-ray crystallographic analysis, and biological evaluation of thiazole derivatives as potent and selective inhibitors of human dihydroorotate dehydrogenase

Human dihydroorotate dehydrogenase (HsDHODH) is a flavin-dependent mitochondrial enzyme that has been certified as a potential therapeutic target for the treatment of rheumatoid arthritis and other autoimmune diseases. On the basis of lead compound 4, which was previously identified as potential HsDHODH inhibitor, a novel series of thiazole derivatives were designed and synthesized. The X-ray complex structures of the promising analogues 12 and 33 confirmed that these inhibitors bind at the putative ubiquinone binding tunnel and guided us to explore more potent inhibitors, such as compounds 44, 46, and 47 which showed double digit nanomolar activities of 26, 18, and 29 nM, respectively. Moreover, 44 presented considerable anti-inflammation effect in vivo and significantly alleviated foot swelling in a dose-dependent manner, which disclosed that thiazole-scaffold analogues can be developed into the drug candidates for the treatment of rheumatoid arthritis by suppressing the bioactivity of HsDHODH.

NOVEL QUINOLINE DERIVATIVES AND THEIR APPLICATIONS

The invention relates to a series of quinoline derivatives of general formula I, pharmaceutically acceptable salts, hydrates, solvates or prodrugs. Thereof M, R1, R2, X, Y and n are defined as claims. And the compounds of general formula I show potent inhibitory activity against c-Met kinase. The present invention further relates to the uses of the compounds, pharmaceutically acceptable salts and hydrates for the preparation of medicaments for the treatment and/or prevention of diseases caused by abnormal expression of c-Met kinase, especially for treatment and/or prevention of cancer.

Novel selective and potent inhibitors of malaria parasite dihydroorotate dehydrogenase: Discovery and optimization of dihydrothiophenone derivatives

Taking the emergence of drug resistance and lack of effective antimalarial vaccines into consideration, it is of significant importance to develop novel antimalarial agents for the treatment of malaria. Herein, we elucidated the discovery and structure-activity relationships of a series of dihydrothiophenone derivatives as novel specific inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH). The most promising compound, 50, selectively inhibited PfDHODH (IC50 = 6 nM, with >14 000-fold species-selectivity over hDHODH) and parasite growth in vitro (IC50 = 15 and 18 nM against 3D7 and Dd2 cells, respectively). Moreover, an oral bioavailability of 40% for compound 50 was determined from in vivo pharmacokinetic studies. These results further indicate that PfDHODH is an effective target for antimalarial chemotherapy, and the novel scaffolds reported in this work might lead to the discovery of new antimalarial agents.

Isothiazoles as active-site inhibitors of HCV NS5B polymerase

Isothiazole analogs were discovered as a novel class of active-site inhibitors of HCV NS5B polymerase. The best compound has an IC50 of 200 nM and EC50 of 100 nM, which is a significant improvement over the starting inhibitor (1). The X-ray complex structure of 1 with HCV NS5B was obtained at a resolution of 2.2 A, revealing that the inhibitor is covalently linked with Cys 366 of the 'primer-grip'. Furthermore, it makes considerable contacts with the C-terminus, β-loop, and more importantly, to the active-site of the enzyme. The uniqueness of this binding mode offers a new insight for the rational design of novel inhibitors for HCV NS5B polymerase.

Biologically selective potassium channel openers having 1,1- diethylpropyl group

To find out selective potassium channel openers (PCOs), we synthesized several 3,5-disubstituted phenylcyanoguanidine derivatives and investigated their structure-activity relationships (SAR). As a result, we discovered selective PCOs having 1,1-diethylpropyl group toward antihypertensive activity.

Synthesis and structure-activity relationships of novel phenylcyanoguanidine derivatives as potassium channel openers

3,5-Di-substituted phenylcyanoguanidine derivatives with halogen, cyano, and/or nitro groups at the 3- and 5-positions of the benzene ring exhibited very strong smooth muscle relaxation activity in vitro, as compared to pinacidil. Among them, N-(3-chloro-5-cyanophenyl)-N'-cyano-N''-tert- pentylguanidine (5s) showed 27-fold more potent activity than pinacidil, and exhibited a stronger and more lasting antihypertensive effect than pinacidil by oral administration to spontaneously hypertensive rats. We propose a new pharmacophore model in which the essential factors for binding to the potassium channel are an NH and a bulky alkyl group.